J

Jeonbuk National University Hospital | Clinical Pharmacology Center

Research site
(Unclaimed)
Location
20 Geonji-ro Deokjin-gu, Jeonju, Seoul, South Korea

Site insights

Top conditions

Top treatments

Lenalidomide
Paclitaxel
Trastuzumab
Pembrolizumab
Cemiplimab
Fianlimab
Rivaroxaban
DA-5207
Trifluridine
Atezolizumab

Parent organization

This site is a part of Jeonbuk National University Hospital

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 48 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing g...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Drug: Evorpacept (ALX148)
Drug: Trastuzumab

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: cemiplimab
Drug: Placebo

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: fianlimab

This study is researching an experimental drug called linvoseltamab, also called REGN5458.Linvoseltamab has previously been studied by itself (withou...

Enrolling
Relapsed Refractory Multiple Myeloma (RRMM)
Drug: Pomalidomide
Drug: Linvoseltamab

This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they...

Enrolling
Pulmonary Disease
Drug: Iohexol (240mgI/mL) with 100kVp
Drug: Iohexol (270mgI/mL) with 100kVp

Antiphospholipid syndrome (APS) has a close association with ischemic stroke; however, the optimal treatment strategy for APS-related stroke has yet...

Enrolling
Ischemic Stroke
Antiphospholipid Syndrome
Drug: Warfarin
Drug: Antiplatelet Drug

To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.

Enrolling
Colorectal Cancer (CRC)
Melanoma
Drug: Cisplatin
Biological: GEN1042

The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the e...

Enrolling
Oral Mucositis
Head and Neck Squamous Cell Carcinoma
Drug: MIT-001 plus CCRT

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Drug: Pelabresib
Drug: Placebo

This is a randomized, double-blind, multicenter, Active Controlled, pivotal clinical trial to assess the efficacy and safety of the novel hexamethyle...

Active, not recruiting
Osteoarthritis
Device: Synovian inj
Device: SP5M002 inj

To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in...

Active, not recruiting
Gastro-Oesophageal Cancer
Biological: Nivolumab
Drug: Paclitaxel

Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be...

Enrolling
Ischemic Stroke
Drug: Placebo group
Drug: Neu2000KWL group

This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patie...

Enrolling
Asthma
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: ARO-MUC5AC

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ARO-RAGE in normal healthy volunteers (NHVs) and in partic...

Enrolling
Asthma
Drug: Placebo
Drug: ARO-RAGE

Trial sponsors

C
Genmab logo
Regeneron Pharmaceuticals logo
S
A
Arrowhead Pharmaceuticals logo
HK inno.N logo
Seoul National University logo
A
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems